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ABSTRACT
MicroRNAs (miRNAs) are short noncoding RNAs
that down-regulate gene expression by silencing
specific target mRNAs. While many miRNAs are
transcribed from their own genes, nearly half map
within introns of ‘host’ genes, the significance of
which remains unclear. We report that transcrip-
tional activation of apoptosis-associated tyrosine
kinase (AATK), essential for neuronal differentiation,
also generates miR-338 from an AATK gene intron
that silences a family of mRNAs whose protein
products are negative regulators of neuronal differ-
entiation. We conclude that an intronic miRNA, tran-
scribed together with the host gene mRNA, may
serve the interest of its host gene by silencing a
cohort of genes that are functionally antagonistic
to the host gene itself.
INTRODUCTION
RNA interference (RNAi) is a physiological pathway in
which short double-stranded RNA (dsRNA) silences spe-
ciﬁc target RNA. In the normal cell, RNAi is triggered by
microRNAs (miRNAs) that are  22-nt long noncoding
RNAs found in diverse organisms from plants to
metazoan animals (1–7). In the predominant mechanism,
the miRNAs bind to imperfectly matched miRNA
response elements (MREs) within the 30-UTR of the
target mRNAs. This leads to the recruitment of key pro-
teins at the site leading to the assembly of the RNAi-
induced silencing complex (RISC) that blocks translation
initiation or elongation, or cleaves the target RNA (7–11).
There are a few hundred experimentally sequenced and
predicted human miRNAs (12,13) that together hold the
potential to regulate thousands of genes impacting a large
variety of biological processes.
The majority of miRNAs are produced from their
own independent transcription units in intergenic regions;
the primary transcript of these genes, pri-miRNA, is
ﬁrst trimmed by the nuclear RNase III-like enzyme,
Drosha (7,14,15). The product, pre-miRNA, is further pro-
cessed in the cytoplasm by the RNase III-like enzyme,
Dicer, to generate the ﬁnal miRNA. In contrast,  40%
of mammalian miRNA sequences map within the introns
of protein-coding ‘host’ genes (16–22), many of which
appear to be conserved across species. The regulation of
such ‘intron-derived’ (or ‘intronic’) miRNAs and their
relationship with their host genes remain a mystery.
Recent evidence that many of them are generated through
unique processing steps bypassing Drosha hints that
potentially novel features of this class of miRNAs still
await discovery (23–25).
To investigate the signiﬁcance of physiologically regu-
lated intronic miRNAs, we took advantage of the fact that
the precursor sequence for miR-338 is located within the
eighth intron (intron-8) of the apoptosis-associated tyro-
sine kinase (AATK) gene (19) and that the AATK kinase
activity plays an essential role in promoting neurite
extension in developing neurons (26–28). This diﬀeren-
tiation process can be induced in cultured neurons by
all-trans retinoic acid (RA), 12-O-Tetradecanoyl phorbol
13-acetate (TPA) and insulin-like growth factor (IGF), all
of which activated de novo AATK gene expression (26).
Although continued overexpression of recombinant
AATK from cloned cDNA also triggered this process,
additional induction of the chromosomal AATK gene
by RA, TPA or IGF promoted faster and more robust
neurite growth (26,28). We hypothesized that optimal
neurite growth requires not only the enzymatic activity
of AATK but also the intronic miR-338 generated from
the chromosomal AATK gene. We further hypothesized
that miR-338 suppresses the translation of a select group
of cellular mRNAs whose protein products are negative
regulators of neurite growth. In the rest of this article, we
provide proof of this novel positive feed-back miRNA
circuit (See Model in Figure 6).
MATERIALS AND METHODS
Neurite growth
Human neuroblastoma SH-SY5Y and M17 cells were
grown on collagen-coated dishes, and induced and
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medium was RPMI1640 supplemented with 10% heat-
inactivated FBS, penicillin (100U/ml) and streptomy-
cin (100U/ml). Cells were photographed in a Nikon
TE2000-E2 imaging station. Neurite diﬀerentiation was
routinely induced by RA (10mM), although IGF (10nM)
and TPA (16nM) (all from Sigma-Aldrich, St. Louis, MO,
USA) were also tested initially and showed similar eﬀects.
Diﬀerentiated cells were quantiﬁed by counting about
400 cells in random ﬁelds at 20  magniﬁcation. Cells
were considered diﬀerentiated if they had at least one pro-
cess (neurite) longer than the cell body. The lengths of
the neurites were measured in at least three independent
experiments and the results expressed as mean standard
error.
Cloning and generation of stablecell lines
Stable Tet-responsive SH-SY5Y (or M17) cell lines were
created using the double-stable Tet-ON system (Clontech,
MountainView,CA, USA). Thecellswere ﬁrst stablytrans-
fected with the pTET-On-Advanced plasmid that produces
the Tet regulator and clones resistant to G418 (150mg/ml)
were selected. Clones with low background but high induc-
tion of luciferase by doxycycline (Dox, a tetracycline deri-
vative; 100ng/ml) from the test plasmid pTRE-Tight-Luc
were then transfected with AATK or ubiquitin-conjugating
enzyme E2Q1 (UBE2Q1) expression plasmids as follows.
To construct the AATK clones the 4206-nt long human
AATK-coding sequence (NM_001080395.1) was ampliﬁed
by RT–PCR using total RNA from 3-day RA-induced SH-
SY5Y cells astemplateandwas clonedintothe EcoRI-XbaI
sites of pTRE-Tight. To insert the intron-8 into the AATK
cDNA, SphI and NdeI restriction sites were ﬁrst created
in the left- and right-ﬂanking exons, respectively, by site-
speciﬁc mutagenesis of appropriate sequences to synon-
ymous codons (e.g. GCCTGT was changed to GCATGC,
to become an SphI site but coding for the same amino acids,
Ala and Cys) using the QuikChange
TM kit (Stratagene,
La Jolla, CA, USA). The 1412-nt long intron-8 of AATK,
along with portions of the ﬂanking exons, was then ampli-
ﬁed with primers containing SphI and NdeI sequences
using genomic DNA as template, restricted with these two
enzymes and cloned into same two sites of the modiﬁed
cDNA clone described above. The Tet-regulator-expressing
SH-SY5Y cell was transfected with the AATK cDNA
clones (with and without intron-8), and stable cell lines
were obtained by hygromycin (150mg/ml) selection. The
AATK genes in these clones are tightly regulated and induc-
ible by Dox (Figure 4A).
The 1269-nt long UBE2Q1-coding sequence plus 599nt
of 30-UTR (total 1868nt) containing all three predicted
MREs was ampliﬁed by RT–PCR using total cellular
RNA as template and cloned within EcoRI and XbaI
sites of pTRE-Tight. The following primers were used
with the restriction sites underlined and the extra
sequences in lowercase added for eﬃcient restriction:
agatacGAATTCATGCAGCAGCCGCAGCCGCAG
and agatacTCTAGAGTTTCTCTTGCTTTAGCAGCA
AAATG. The reverse transcription was performed at
658C for 3h using Tth DNA polymerase (Roche),
followed by PCR using a Taq:Pfu polymerase mix
(20:1) and the following parameters: initial denaturation
at 948C, 4min; 40 cycles (948C, 40s; 658C, 30s; 728C,
4min); ﬁnal extension at 728C, 8min; hold at 48C. The
product was gel-puriﬁed, restricted and cloned. The
three MRE sites (Figure 2A) were sequentially mutated
(GCUG ! CGAC) using the QuikChange
TM kit. The
C351A mutant (TGC ! GCC) of this clone was then
constructed using the same kit.
Transfection
Plasmids were prepared using the Midi kit (Qiagen,
Valencia, CA, USA). Transfection of cultured cells with
plasmids, synthetic siRNA (Ambion, Austin, TX, USA),
miRIDIAN miRNA Mimics (Dharmacon, Lafayette, CO,
USA)and20-O-methylantagomirs(Ambion)wasperformed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
as described (18). Three siRNAs each were designed against
each of the targets [UBE2Q1, microtubule-associated pro-
teins 1A (MAP1A), neuro-oncological ventral antigen 1
(NOVA1)] and were all eﬀective within a range of 65–80%
knockdown, showing speciﬁcity. However, we have pro-
vided results with the most eﬀective siRNA for brevity
(Table 1). Control luciferase siRNA has been described (29).
Assays
Quantitative real-time reverse transcription PCR (qRT–
PCR) with total cellular RNA was performed as described
(30) using mRNA-speciﬁc primers (Table 1). Genomic
ampliﬁcation was ruled out by three reasons: (i) the RNA
isolation procedure involved RNase-free DNaseItreatment;
(ii) no product was obtained in control PCR without reverse
transcription; (iii) the two primers of a pair were designed
against two exons spanning an intron, and a single product
was generated in qRT–PCR, corresponding in size to the
intronless processed mRNA. We have shown product bands
from a representative cycle (usually between 25 and 30)
when ampliﬁcation was still exponential.
Immunoblots (western blot) were performed with 40mg
total cell lysate loaded per SDS–PAGE lane. The primary
antibodies were: rabbit polyclonal antibody against human
ribosomal L13a (31), rabbit anti-AATK (kindly provided
by Dr Stacey Baker and Dr E. P. Reddy); rabbit anti-
MAP1A (Santa Cruz Biotechnology, Santa Cruz, CA,
USA); goat anti-NOVA1 (Santa Cruz Biotechnology);
polyclonal mouse anti-UBE2Q2 (Novus Biologicals,
Littleton, CO, USA), which was found to cross-react
with UBE2Q1 due to substantial homology (not shown);
TAF-4, TAF-6 (Sigma-Aldrich); and monoclonal mouse
anti-GAPDH (Ambion). HRP-conjugated secondary anti-
bodies (Sigma-Aldrich) were developed with the ECL
method using the SuperSignal West Dura substrate
(Pierce/Thermo Scientiﬁc, Rockford, IL, USA). The ECL
luminescence and EtBr ﬂuorescence of DNA in agarose
gels were captured in Fujiﬁlm LAS-3000.
The miRNA levels were measured using the mirVana kit
(Ambion) and the manufacturer’s procedure, based on
solution hybridization with labeled antisense RNA, fol-
lowed by RNase digestion, gel electrophoresis and autora-
diography. For northern quantitation of AATK and
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ampliﬁed and
32P-labeled by PCR, was used as probe.
To analyze the ribosomal proﬁle, SH-SY5Y cells were
treated with RA alone or transfected with the indicated
antagomirs as well as treated with RA. Cells were lyzed 4
days later and the polysomal mRNA was isolated exactly
as described (31). Control RA-untreated cells were pro-
cessed similarly. The preparation was analyzed by centri-
fugation through 20% sucrose. The ribosome-bound
(polysomal) pellet from the bottom and the free RNA
from the top of the tube were collected, deproteinized
and subjected to qRT–PCR using mRNA-speciﬁc primers
(Table 1). Portions of the isolated RNA were tested for the
presence of 18S and 28S rRNA. Where mentioned, poly-
somal fractions were incubated with puromycin (90mg/ml)
for 1h at 48C, followed by centrifugation through sucrose
as before, and the dissociation of GAPDH mRNA from
the polysomal to the ‘free’ fraction (top of gradient) was
tested by RT–PCR of the fractions.
Statistical analysis
Changes were analyzed by one-way ANOVA and by
Student’s t-test with Bonferroni correction. All numerical
data were collected from at least 3 separate experiments.
Results were expressed as mean SEM (error bars in
graphs). Diﬀerences were considered to be signiﬁcant at
P<0.05.
RESULTS
Neurite growth in cultureparallels activation ofthe
AATK geneand generation of miR-338
We ﬁrst tested if induction of the chromosomal AATK
gene indeed generated miR-338. We induced
diﬀerentiation in two kinds of neuroblastoma cells, M17
and SH-SY5Y, by treating with RA, and conﬁrmed the
development of the neurites (Figure 1A), with robust
growth observed by day 4. In both cells, AATK mRNA
and protein levels rose to optimal levels by days 2 and 3,
respectively (Figure 1B). When we measured miR-338
levels, we detected a strong and sustained increase,
whose kinetics matched that of the AATK mRNA
(Figure 1B), as one would expect if both are processed
from the same primary transcript. We note that maximal
neurite length was previously reported on day 7 and 8
after induction of the AATK gene (26); however, as our
main focus is on the eﬀect of miR-338, which is synthe-
sized before AATK protein is translated, we chose the
4-day time point for routine assays to strike an optimal
balance between the eﬀects of AATK kinase activity and
the eﬀects of miR-338. Control b-actin mRNA and other
miRNAs (miR-139, miR-143) were unaﬀected at all times.
To directly demonstrate an essential role of AATK in
neurite growth, we performed a control experiment in
which AATK expression was knocked down by pretrans-
fection with speciﬁc siRNA. As shown (Figure 1B, lowest
panel), this resulted in degradation of AATK mRNA and
loss of AATK protein, causing little or no neurite growth
(Figure 1A, lowest panel). In contrast, the miR-338 levels
remained largely unaﬀected, which supports the view that
intronic miRNA is produced in the nucleus before the
processed mRNA is exported to the cytoplasm, where
RISC-mediated degradation of mRNA occurs. Together,
these results show a strong correlation between miR-338
biogenesis and AATK gene induction and also demon-
strate an essential role of the native AATK enzyme in
RA-induced diﬀerentiation.
Each pre-miRNA precursor can potentially generate
two processed species, viz., the miRNA from one strand
that enters the RISC and the miRNA
  that generally acts
as the carrier strand but nonetheless may potentially func-
tion as miRNA as well (32). However, we could not detect
any miR-338
  by northern under the same conditions that
revealed the induction of miR-338 (data not shown). We
presume that miR-338
  is rapidly degraded upon biogen-
esis and thus not relevant for our studies.
Translational silencing of miR-338 targetsoccurs
during neurite growth
First, in order to identify target mRNAs regulated by
miR-338, we used multiple search programs, namely,
PicTar (33), miRANDA (12), TargetScan (34,35) and
DIANA (36), and then visually veriﬁed the top scorers
from each program by the comprehensive set of miR-
target base-pairing rules such as multiple MRE and by
conservation across species (8,34–36). Based on these, we
selected ﬁve candidates for further study (Figure 2A): zinc-
ﬁnger protein 238 (ZNF238, also called C2H2-171;
NM_205768), DAB2-interacting protein (DAB2IP;
NM_032552), MAP1A (NM_002373), NOVA1
(NM_002515) and UBE2Q1 (NM_017582). All the pre-
dicted MREs in these targets perfectly paired with the
seed region nucleotides 2–7at the 50-end of miR-338, con-
sidered essential for miRNA function (Figure 2A).
Table 1. siRNA and primer sequences
siRNA Sequence
AATK 50 GGGCCCUGAAGCACAGCAAdTdT 30
30 dTdTCCCGGGACUUCGUGUCGUU 50
MAP1A 50 GUGGGCAGGCAAUAGUAAAdTd 30
30 dTdTCACCCGUCCGUUAUCAUUU 50
NOVA1 50 GCACAGCAGGUCUGAUAAUdTdT 30
30 dTdTCGUGUCGUCCAGACUAUUA 50
UBE2Q1 50 GGGCAAGAAAUCUGAAGAUdTdT 30
30 dTdTCCCGUUCUUUAGACUUCUA 50















The siRNAs were designed as described before (29,30) with dTdT at the 30
termini. The qRT–PCR primers were designed such that the product
length was in the 120–150bp range.
5234 Nucleic Acids Research, 2008, Vol. 36, No. 16Translational arrest by miRNA involves a variety of
mechanism that may operate at either initiation or elonga-
tion stage of translation and may lead to dissociation of
the target mRNA from the polysomal or a polysome-like
fraction with or without destabilization of the mRNA
(9,10,11,37). To investigate the status of our candidate
miR-338 target mRNA, we isolated the polysomal and
free (nonpolysomal) mRNA fractions from RA-treated
and untreated cells. We ﬁrst conﬁrmed the identity of
the fractions by the presence of ribosomal proteins and
rRNAs speciﬁcally in the ribosomal/polysomal fraction
at the bottom and their absence in the ‘free’ fraction
(Figure 2B). We then determined the speciﬁc mRNA
levels in these fractions by qRT–PCR. Note that we
have presented results of SH-SY5Y cells only to conserve
space, but the M17 cells produced essentially similar
results that are not shown. Our results (Figure 2C) show
that upon RA treatment, large portions of all ﬁve mRNAs
were released free from the polysomal fraction. A concom-
itant reduction in the protein levels was evidenced by
immunoblot using antibodies available against three
target proteins. These changes did not occur in the
RA-untreated cells or to the control GAPDH mRNA.
Incubation of the polysomal fraction with puromycin
(see Materials and methods section) led to release of the
GAPDH mRNA to the top of the gradient, conﬁrming the
validity of the fractionation procedure (data not shown).
TAF-4 and TAF-6, two subunits of the general transcrip-
tion factor TFIID, also acted as negative controls since
their protein levels remained unaﬀected by RA; their poly-
somal association was, therefore, not studied. Overall, we
conclude that translational silencing of the miR-338 target
genes correlated with neurite growth.
Antagomirs are short synthetic RNAs that are antisense
to speciﬁc miRNAs and inhibit the function of the
miRNAs against which they are designed (38). To obtain
direct evidence that the observed silencing was indeed due
to miR-338, we transfected the cells with antagomir-338,
which restored polysomal association of the target
mRNAs as well as protein levels (Figure 2C). Control
antagomirs against three irrelevant miRs (miR-9, -128,
-138) had no eﬀect on the polysomal association or protein
levels of the targets, as shown for UBE2Q1 as representa-
tive (Figure 2C), even though these three miRs are natu-
rally abundant in neuronal tissues including the CNS
(16,39). Together, these results validate selected miR-338
targets predicted by bioinformatics and demonstrate that
they are indeed silenced during neuronal diﬀerentiation.
Figure 1. Neuronal diﬀerentiation parallels AATK mRNA and miR-338 levels. (A) Photomicrograph of M17 and SH-SY5Y cells after 4 days of RA
treatment or no treatment. (B) Northern measurement of mRNAs and miRNAs and immunoblot of the proteins in two diﬀerent cells after the
indicated days of RA treatment. In the lowest panels, the M17 cells were transfected with AATK siRNA (Table 1) 18h before the addition of RA.
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aswell asmiR-338
Having shown that miR-338, originating from an AATK
intron, indeed translationally silences its predicted targets,
we sought to determine the relative eﬀects of miR-338 and
AATK on neuron diﬀerentiation. We ﬁrst knocked down
AATK protein expression by speciﬁc synthetic siRNA,
which almost completely abrogated RA-mediated diﬀeren-
tiation (Figure 3, lane 3), conﬁrming the indispensable role
of AATK (26–28). Neutralization of miR-338 by antago-
mir-338 also strongly reduced neurite length by about 50%
without aﬀecting AATK protein levels (Figure 3, lanes 5
and 6), suggesting a stimulatory role of miR-338 in diﬀer-
entiation. Joint transfection with anti-AATK siRNA and
antagomir-338 was as inhibitory as anti-AATK siRNA
alone (Figure 3,lane 7). Control siRNA (against luciferase)
and control antagomirs aﬀected neither AATK levels nor
diﬀerentiation (Figure 3, lanes 8–10). Clearly, AATK
kinase is absolutely essential for diﬀerentiation whereas
miR-338 serves as an accessory to promote optimal neurite
growth. This is consistent with the generally accepted
notion that miRNAs are not major developmental regula-
tors but rather support developmental transcriptional pro-
grams (40).
Recombinant AATK andmiR-338 can promoteoptimal
neuronal differentiation without RA
To rule out any indirect eﬀect of RA on the neurons and
clearly dissociate the role of miR-338 from AATK activ-
ity, we created neural cell lines containing Tet-inducible
Figure 2. Putative miR-338 response sites and translational status of target mRNAs. (A) Multiple predicted MRE-miR-338 hybrids for the indicated
target genes are depicted in the pattern shown above, i.e. for each hybrid, the top sequence is MRE and bottom is miR-338. The seed sequence of miR-338
is underlined. For each target, the number on the left is the position of this nucleotide in the NCBI entry (whose accession numbers are provided in the
Results section). (B) Validity of ribosomal fractionation. The ribosome-free fraction from the top and the ribosomal/polyribosomal fraction from the
bottom of the gradient were analyzed for the ribosomal protein L13a in western blot (left) and for the presence of rRNA by agarose gel electrophoresis
(right). Note that similar fractions were analyzed in (C) as well. Day 0 and 4 mean no RA treatment and 4 days of RA treatment, respectively. (C)
Polysomal association of target mRNAs. SH-SY5Y cell were treated as shown on left (i.e. RA treatment with or without transfection with antagomirs
against miR-9, -128, -138). Before (day 0) and after 4 days (day 4) of RA treatment, the polysomal and free RNAs were quantiﬁed by qRT–PCR and
representative samples analyzed on 2% agarose–EtBr gels and photographed under UV light (left panels). Immunoblot (western) of total extract of the
corresponding cells shows the diﬀerent protein levels (right panels). ND, not done.
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permit the study of neuronal diﬀerentiation without activ-
ating the endogenous AATK gene by RA. Basically, two
types of AATK plasmids were constructed using the
pTRE-Tight Tet-ON vector, one containing the AATK
protein-coding sequence only (without introns) (26) and
the second, containing coding sequence plus intron-8 in its
natural position. The plasmids were transfected into
SH-SY5Y cells constitutively expressing the Tet trans-
activator, and stable cell lines were obtained by hygromy-
cin selection. These cells were ﬁrst conﬁrmed to express
AATK (Figure 4A); both intronless and intron-containing
AATK transgenes produced AATK protein following
addition of Dox without RA (Figure 4A), as expected.
Biogenesis of miR-338 from the Dox-induced intron-
containing AATK (lane 2) but not from the intronless
gene (lane 4) was conﬁrmed. Both cell types also under-
went diﬀerentiation (Figure 4B, panels 2 and 4). Most
signiﬁcantly, however, the average length of neurites
expressing intronless AATK (Figure 4A, lanes 4 and 5)
was considerably shorter than those expressing intron-
8-containing AATK (Figure 4A, lane 2). The length of
the former could be restored by transfection of synthetic
miR-338 (Figure 4A, lanes 6 and 7), proving that the role
of intron-8 was to provide miR-338. Control miR-139 had
no eﬀect (Figure 4A, lane 8). These results lend additional
support to our hypothesis that miR-338 from intron-8 of
AATK is essential for optimal neurite length.
If the role of miR-338 is indeed to silence key mRNA
targets, we reasoned that silencing the same targets with
an alternative approach would also have a similar eﬀect,
i.e. help neurite growth. To test this, we knocked down
MAP1A, NOVA1 and UBE2Q1 with synthetic siRNA.
These three were chosen because, as shown in Figure 1,
their antibodies were available to monitor silencing at the
protein level. The siRNAs were transfected into SH-SY5Y
cells expressing intronless AATK mRNA induced by Dox.
Loss of the speciﬁc target protein was conﬁrmed by immu-
noblot that revealed 70–80% reduction whereas control
luciferase siRNA had no eﬀect (data not shown). All
three siRNAs increased neurite lengths to various extents
in the presence of AATK activity but without miR-338
(Figure 4A, lanes 9–11). We conclude that all three
Figure 3. Induced endogenous intronic miR-338 promotes neurite
growth. Standard SH-SY5Y monolayer was treated with RA and/or
transfected with siRNA or antagomirs in the following combination,
and at 4 days thereafter, neurite lengths were measured and then cell
extracts were made to determine AATK and control proﬁlin protein
levels by immunoblot. 1, no treatment; 2, RA alone; 3, RA+anti-
AATK siRNA (50nM); 4, RA+anti-Luc siRNA (100nM);
5, RA+antagomir-338 (50nM); 6, RA+antagomir-338 (100nM); 7,
RA+anti-AATK siRNA (50nM)+antagomir-338 (50nM); 8,
RA+control antagomir-9 (100nM); 9, RA+control antagomir-128
(100nM); and 10, RA+control antagomir-138 (100nM).
Figure 4. Dox-inducible coexpression of recombinant AATK and
its intronic miR-338 is suﬃcient to promote optimal neurite growth.
Note that there is no RA treatment in this panel of experiments, and
therefore, the endogenous AATK gene is silent. (A) Measurement of
neurite growth. SH-SY5Y cells-containing stable AATK transgene with
or without intron-8 were induced with Dox where indicated for 4 days
(+) or 6 days (++), or uninduced ( ). Synthetic miR-338 mimic
was transfected where indicated (+50nM; ++100nM). Control miR-
139 (100nM) was transfected in lane c. Transfection of siRNA
(50nM) against MAP1A, NOVA1 or UBE2Q1 was done in lanes M, N
and U, respectively. Neurite length was measured and standard error bars
from three experiments are shown. AATK and control proﬁlin
protein levels in the cell extracts were determined by immunoblot.
In the miR-338 panel, intron-8-generated miR-338 was detected as
described in Materials and methods section. ND, not done. (B)
Representative photomicrographs of cells corresponding to data 1, 2, 4
and 6 of panel A.
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suppressive functions. Note that miR-338, when
expressed, promoted even longer neurites (lanes 6, 7),
which is expected if miR-338 should silence other antag-
onistic genes as well.
Overexpression of anunsilenced miR-338target
inhibitsneuronal differentiation
In a reciprocal approach, we tested if overexpression of a
miR-338 target is in fact detrimental to neurite growth. To
accomplish this, we chose UBE2Q1, which contained
three prospective MREs (Figure 2), and constructed Tet-
inducible clones of the full-length UBE2Q1-coding
sequence engineered to contain an N-terminal 6xHis-tag,
followed by either a wild type 30-UTR or a mutated
30-UTR in which the GCUG sequence of all three
MREs were mutated to CGAC such that they should no
longer bind miR-338. We selected stable transfectants of
SH-SY5Y cells containing these expression cassettes,
induced the UBE2Q1 transgene with Dox and also acti-
vated the diﬀerentiation of the cells with RA. We moni-
tored the expression of the recombinant His-tagged and
endogenous UBE2Q1 proteins and measured the average
neurite length. The results (Figure 5) showed that Dox
indeed induced His-tagged UBE2Q1 that reacted with
both anti-UBQ and anti-His antibodies (lanes 1 and 4).
Control uninduced cells (lane C) showed only the endo-
genous UBQ band and no His-UBQ, also demonstrating
tight repression by the Tet repressor. RA silenced the His-
UBE2Q1 protein levels only when the transgene had func-
tional MRE sites (lane 2) and not when the MREs were
mutated (lane 5). The endogenous UBE2Q1 was always
silenced by RA, as it contained the natural MRE sites.
Direct evidence that the mutant MREs in the transgene
were indeed mir-338 resistant was obtained by transfection
of synthetic miR-338 that silenced the MRE-wild-type
transgene (lane 3) but not the MRE-mutant (lane 6).
When we measured the diﬀerentiation phenotype of
these cells, RA-induced neurites of cells with low
UBE2Q1 levels (lane 2) were about 60% longer than
those with high UBE2Q1 levels (lane 5). Knockdown of
the mir-338-resistant UBE2Q1 transgene with transfected
siRNA also restored optimal neurite length (lane 7).
Finally, members of the ubiquitin-conjugating enzyme
E2 family contain a C-terminal catalytic domain, a key
residue of which is a conserved Cys that forms thiol–
ester linkage with the C-terminus of ubiquitin protein
ligase enzymes, E3, an essential intermediate in ubiqui-
tin-mediated protein degradation pathway (41). To
obtain evidence that the neurite suppressive role of
UBE2Q1 may be due to its conjugating function, we
mutated the corresponding Cys351 of UBE2Q1 to Ala
in the miR-338-resistant clone and expressed the recombi-
nant C351A mutant in the same Dox-inducible manner.
This mutant protein failed to inhibit neurite growth (lane
8; compare with lane 5). Together, these results prove that
high ubiquitin-conjugating activity of UBE2Q1 is indeed
detrimental to neurite growth, oﬀering a persuasive reason
for the cell to silence it by miR-338, generated during
normal neuronal diﬀerentiation.
DISCUSSION
In this communication, we demonstrate that an intronic
miRNA can silence genes that are functionally antagonis-
tic to its host gene product, thus creating a positive feed-
back loop that assists the physiological role of the host
gene. Such an intronic miRNA can be viewed as a ‘slave’
serving the interests of its ‘master’ host gene on demand.
The proposed mechanism is summarized in Figure 6.
The role of miR-338 in neuronal growth, as reported
here, is consistent with previous studies in which a number
of miRNAs, including miR-338, were detected in primary
mammalian neurons (16,42). Although we do not know
exactly how the various miR-338 targets may inhibit
neurite growth, they clearly utilize diverse mechanisms
working in parallel. Ubiquitin-mediated protein degrada-
tion, for example, regulates remodeling and degradation
of neuronal processes, including dendritic pruning (43).
Dysregulation of E2 activity is central to Wallerian
axonal degeneration (43), characteristic of conditions
such as multiple sclerosis. Conceivably, UBE2Q1 may be
involved in the destabilization of key proteins essential in
neurite growth. The high molecular mass MAP1A and
Figure 5. Overexpression of recombinant UBE2Q1 protein impedes
neurite growth in SH-SY5Y cells. Recombinant UBE2Q1 transgene
with (lanes C and 1–3) or without (lanes 4–8) functional MREs was
induced with Dox (+) or not induced ( ). Cells were treated with RA
(+) (to activate endogenous AATK and miR-338 synthesis) or left
untreated ( ). Lane 8 expressed the C351A mutant recombinant
UBE2Q1 protein. Transfection with exogenous miR-338 mimic (m)
and anti-UBE2Q1 siRNA (s) were performed where indicated. In the
three immunoblot (western) panels, cell lysates were probed with (from
top to bottom) anti-UBE2Q1, anti-His and antiproﬁlin antibodies.
Note that the UBE2Q1 antibody reacts with both the His-tagged
recombinant and the endogenous protein, whereas the His antibody
reacts with the recombinant only, conﬁrming the identity of the two
bands. To achieve a substantial separation between the His-tagged and
endogenous protein bands (that diﬀer by  2000 Mr), the SDS–PAGE
was performed in a 30-cm tall gel apparatus (normally used for DNA
sequencing runs).
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vous system (44). Expression of MAP1B is high during
early stages of neuronal development and is down-
regulated in the adult (45). Interestingly, MAP1A exhibits
a reciprocal pattern of expression; it is all but absent in
developing axonal ﬁbers but reaches its peak in the adult
brain, when neuronal diﬀerentiation is over (45). This is
consistent with our ﬁnding that MAP1A levels may be low
in developing neurons. Moreover, MAP1B mRNA does
not contain a recognizable MRE for miR-338 (data not
shown). Thus, although the exact function of the MAPs in
neuronal diﬀerentiation is currently unclear, it is obvious
that the use of miR-338 oﬀers a way to preferentially
silence MAP1A over MAP1B. NOVA1 is recognized as
a regulator of brain-speciﬁc splicing (46) and we presume
that it promotes the generation of splice variants of spe-
ciﬁc transcripts whose products suppress diﬀerentiation in
the resting neuron. The DAB2IP gene is a tumor suppres-
sor and its promoter is epigenetically silenced in various
cancers, consistent with its general growth inhibitory role
(47,48). It appears that the nerve cells have evolved the
miRNA-based alternative and rapid mechanism to silence
DAB2IP translation rather than transcription. C2H2-171,
a novel POZ-domain zinc-ﬁnger protein (also known as
ZNF238 or RP58, repressor protein 58kDa) is a sequence-
speciﬁc transcriptional repressor in brain, and other mem-
bers of this family also function as repressors and/or
developmental regulators (49). It is, therefore, reasonable
to speculate that C2H2-171 represses speciﬁc developmen-
tal genes in the resting neurons and hence, must be
silenced in order to activate such genes.
For the risks of toxicity and saturation of the RISC
machinery, we did not attempt to silence all these
miR-338 targets simultaneously by siRNA. It is also pos-
sible that there are other miR-338 targets in the diﬀeren-
tiating neuron that we have not studied and that their
combined silencing by miR-338 will boost neuron length
most optimally. Nonetheless, in continuing our qRT–
PCR-based screen of the polysomal fractions with and
without antagomir-338 (similar to Figure 2C), we found
that two other potential targets, highly scored by
MIRANDA, are also regulated in the same manner
(data not shown). These are: cerebellar degeneration-
related protein 1 (CDR1) and 26S proteasome non-
ATPase regulatory subunit 7 (PSMD7). There is in fact
evidence that both are involved in neuronal degeneration
and/or remodeling (50,51), and conceivably, need to be
silenced for optimal neuron growth. Conﬁdence in our
study is further bolstered by the lack of this regulation
in some other predicted targets, e.g. TAF-4 and TAF-6
(Figure 2C), which are TATA-binding protein-associated
factors that function as subunits of the general transcrip-
tion initiation factor TFIID and thus have no obvious
biochemical basis to be detrimental to cell growth.
Although our model (Figure 6) is presented in terms of
miR-338, the universality of this mechanism forother regu-
lated intronic miRs is justiﬁable. In a recent study (52),
miR-208, originating from an intron in the a-myosin
heavy chain (aMHC) gene of the heart, was shown to
silence the thyroid hormone receptor-associated protein 1
(THRAP1, also known as TRAP240), which in turn regu-
lated the transcription of the bMHC gene. Thus, the
aMHC gene, in addition to encoding a major cardiac con-
tractile protein, also regulated bMHC in response to stress
and hypothyroidism. Even though the full regulatory cir-
cuitry of miR-208 remains to be elucidated, we speculate
that it regulates a family of targets in the heart to further
aMHC function. In another potential example, miR-151
resides within intron-21 of the gene for focal adhesion
kinase (FAK) (19), transcription of which is up-regulated
in proliferative diseases such as cancer (53). It, therefore,
appears logical that a number of bioinformatically
predicted targets of miR-151 are regulators of cell cycle,
whose expression is either expected or demonstrated to be
reduced in various forms of cancer; such targets include
SCC-112 (54), chromosome-associated kinesin KIF4A
and growth arrest-speciﬁc protein GAS-2 (55).
Several unique features and advantages of our mecha-
nism deserve mention: (i) It is an example of a regulatory
noncoding RNA within a coding RNA. Coupled synthesis
of the miRNA and its host transcript ensures that the
miRNA will be available to assist the host gene whenever
the latter is activated, but at no other time. This may also
be a reason the miRNA evolved to be located within the
host gene. (ii) As this regulation works in the form of
RNA, it is independent of the biochemical nature of the
protein product of either the host gene or the target genes.
For example, it would have worked just as well if AATK
were say, a neural transcription factor rather than a
kinase. (iii) A given miRNA from one host gene can
silence multiple antagonistic genes simultaneously. (iv)
The concentration of the intronic miRNA may discrimi-
nate between high- and low-aﬃnity MREs and thereby
ﬁne-tune their silencing. (v) This concentration will be
Figure 6. Model for silencing of antagonistic genes by intronic miRNA.
A pathway (e.g. diﬀerentiation) is activated by the product of the gene
(e.g. AATK) that also hosts the miRNA (e.g. miR-338) that silences
antagonistic genes, providing optimal stimulation of the pathway. Note
that many variations of the theme are possible. For example, the
mechanism would also apply to examples of repression if the ﬁrst
gene were a repressor of the pathway; the miRNA would then silence
a family of antagonistic activators of the pathway to promote optimal
repression.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5239regulated by the same signals and pathways that regulate
the host gene promoter (e.g. RA, TPA, IGF for AATK).
(vi) Though the mechanism of processing of the intronic
miRNA is still not fully clear, it may be strategically regu-
lated by the alternate splicing decisions of the intron. (vii)
The inducible intronic miRNA oﬀers a reversible silencing
mechanism, i.e. when the host gene transcription will be
shut oﬀ upon cessation of the activating signal, the target
protein levels will also be restored. (viii) Although in our
example, AATK is a ‘positive’ regulator of diﬀerentiation
and the target genes are ‘negative’, the mechanism would
work the same way if it were the reverse, i.e. if the host
gene were a repressor of a pathway and the targets were
activators of the same pathway. In fact, one can readily
imagine more elaborate variations of this basic theme. For
example, as mentioned before, miR-208 seems to help the
function of its host gene (aMHC) by silencing the tran-
scription regulator of the target bMHC gene without
directly aﬀecting bMHC mRNA (52). Indeed, the func-
tional antagonism of the target genes toward the host
gene is the fundamental aspect of the mechanism.
Clearly, the coevolution of a miRNA-hosting intron and
its multiple target gene MREs would be an interesting
paradigm to study.
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